Literature DB >> 30633900

GABAAR Modulator for Postpartum Depression.

Istvan Mody1.   

Abstract

During the postpartum period, the brain's inhibitory GABAA receptors may not recover in time following their reduced numbers during pregnancy. This is likely the cause of postpartum depression prevalent in ∼12% of childbearing women. A new therapy for this condition consists of administering a synthetic neurosteroid during the postpartum period to alleviate the mood disorder. To view this Bench to Bedside, open or download the PDF.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30633900     DOI: 10.1016/j.cell.2018.12.016

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  6 in total

1.  p62/SQSTM1 droplets initiate autophagosome biogenesis and oxidative stress control.

Authors:  Eeva-Liisa Eskelinen; Shun Kageyama; Masaaki Komatsu
Journal:  Mol Cell Oncol       Date:  2021-03-09

2.  Allopregnanolone, the Neuromodulator Turned Therapeutic Agent: Thank You, Next?

Authors:  Graziano Pinna
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-14       Impact factor: 5.555

3.  Allopregnanolone-based treatments for postpartum depression: Why/how do they work?

Authors:  Najah Walton; Jamie Maguire
Journal:  Neurobiol Stress       Date:  2019-10-24

4.  Neurosteroids as novel antidepressants and anxiolytics: GABA-A receptors and beyond.

Authors:  Charles F Zorumski; Steven M Paul; Douglas F Covey; Steven Mennerick
Journal:  Neurobiol Stress       Date:  2019-09-27

Review 5.  Experience-Regulated Neuronal Signaling in Maternal Behavior.

Authors:  Ileana Fuentes; Yoshikazu Morishita; Sofia Gonzalez-Salinas; Frances A Champagne; Shusaku Uchida; Gleb P Shumyatsky
Journal:  Front Mol Neurosci       Date:  2022-03-24       Impact factor: 5.639

6.  Brexanolone for the treatment of patients with postpartum depression.

Authors:  K E Morrison; A B Cole; S M Thompson; T L Bale
Journal:  Drugs Today (Barc)       Date:  2019-09       Impact factor: 2.245

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.